Published in Ann Neurol on November 01, 1994
Ecstasy and neurodegeneration. BMJ (1996) 2.93
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry (2000) 1.49
Neuroimaging in the early diagnosis of neurodegenerative disease. Transl Neurodegener (2012) 0.91
Four decades of neurodegenerative disease research: how far we have come! J Neurosci (2009) 0.84
Parkinson's disease. Subcell Biochem (2012) 0.82
Dorsal striatal dopamine, food preference and health perception in humans. PLoS One (2014) 0.80
The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. J Neurosurg (2009) 0.79
Modulation of impulsivity and reward sensitivity in intertemporal choice by striatal and midbrain dopamine synthesis in healthy adults. J Neurophysiol (2015) 0.77
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 7.03
Multiple receptors for dopamine. Nature (1979) 5.51
Parkinson disease in twins: an etiologic study. JAMA (1999) 5.45
Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 4.54
Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 4.42
Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med (1999) 4.27
Natural history of normal-tension glaucoma. Ophthalmology (2001) 4.00
Levodopa failure in chronic manganism. Neurology (1994) 3.80
A meta-analysis of the effect of Bacille Calmette Guérin vaccination on tuberculin skin test measurements. Thorax (2002) 3.65
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
The effect of age on the nerve fiber population of the human optic nerve. Am J Ophthalmol (1984) 2.94
Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol (2001) 2.84
Criteria for diagnosing Parkinson's disease. Ann Neurol (1992) 2.78
L-dopa in postencephalitic parkinsonism. Lancet (1969) 2.72
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
A scoring error in the Mini-Mental State test. Can J Psychiatry (1993) 2.69
Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology (1985) 2.58
The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. Ann Intern Med (1987) 2.58
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47
Bromocriptine in Parkinsonism. Br Med J (1974) 2.44
Aetiology of Parkinson's disease. Lancet (1984) 2.32
Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol (2001) 2.31
Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Ann Neurol (1999) 2.26
Granulocytic sarcoma in childhood leukemia: imaging features. Radiology (1994) 2.26
Risk factors for clustering of tuberculosis cases: a systematic review of population-based molecular epidemiology studies. Int J Tuberc Lung Dis (2008) 2.21
Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol (1990) 2.18
Smoking and Parkinson's disease in twins. Neurology (2002) 2.15
The rate of progression of scotomas in glaucoma. Am J Ophthalmol (1986) 2.13
The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. Magn Reson Imaging (1999) 2.11
Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation (1999) 2.09
Vocal cord paralysis in the Shy-Drager syndrome. J Neurol Neurosurg Psychiatry (1979) 2.04
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med (1992) 2.01
Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology (1999) 1.97
Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol (1997) 1.94
Reaction time in Parkinson's disease. Brain (1981) 1.92
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology (2011) 1.90
Survival analysis for success of Molteno tube implants. Br J Ophthalmol (2001) 1.88
Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology (2004) 1.87
X-linked scapuloperoneal syndrome. J Neurol Neurosurg Psychiatry (1972) 1.87
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
L-dopa in idiopathic parkinsonism. Lancet (1969) 1.86
A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet (1998) 1.84
Diagnostic accuracy of self collected vaginal specimens for human papillomavirus compared to clinician collected human papillomavirus specimens: a meta-analysis. Sex Transm Infect (2005) 1.81
Hypotension caused by L-dopa. Br Med J (1970) 1.81
Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am J Ophthalmol (1988) 1.78
The area of the neuroretinal rim of the optic nerve in normal eyes. Am J Ophthalmol (1987) 1.78
Positron emission tomography in manganese intoxication. Ann Neurol (1989) 1.78
The hypothalamus in Parkinson disease. Ann Neurol (1978) 1.74
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res (1984) 1.71
The normal human optic nerve. Axon count and axon diameter distribution. Ophthalmology (1989) 1.69
Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov Disord (2001) 1.68
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol (1992) 1.67
Selegiline and mortality in Parkinson's disease. Ann Neurol (1996) 1.67
Epidemiologic health survey of grain elevator workers in British Columbia. Am Rev Respir Dis (1980) 1.67
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol (2000) 1.65
Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet (1986) 1.65
Cardiovascular reflexes in Parkinsonism. Clin Sci (1971) 1.62
Neuroretinal rim area in early glaucoma. Am J Ophthalmol (1985) 1.61
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J (1971) 1.60
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology (2008) 1.60
Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis (1993) 1.60
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology (1996) 1.60
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Selegiline in Parkinson's disease. BMJ (1995) 1.58
Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci (1984) 1.57
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol (1986) 1.56
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry (2000) 1.49
Receiver operating characteristic curve analysis in the prediction of carpal tunnel syndrome: a model for reporting electrophysiological data. Muscle Nerve (1993) 1.48
Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry (1974) 1.47
Adoption of guidelines for Universal Precautions and Body Substance Isolation in Canadian acute-care hospitals. Infect Control Hosp Epidemiol (1990) 1.47
Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol (1991) 1.46
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol (1997) 1.45
Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res (1988) 1.44
Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol (2001) 1.44
Lymphocytes from the site of disease but not blood lymphocytes indicate the cause of arthritis. Ann Rheum Dis (1985) 1.44
Parkinsonism caused by petroleum waste ingestion. Neurology (1994) 1.42
PCR analysis of platelet mtDNA: lack of specific changes in Parkinson's disease. Mov Disord (1993) 1.42
The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J Nucl Med (1991) 1.42
Action of dopamine on the human iris. Br Med J (1969) 1.42
Asthma, asthmalike symptoms, chronic bronchitis, and the degree of bronchial hyperresponsiveness in epidemiologic surveys. Am Rev Respir Dis (1987) 1.41
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA (1988) 1.41